King's College London

Research portal

The Role of PET-CT Imaging in Prostate Cancer

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)373-391
Number of pages19
JournalSeminars in Ultrasound, CT and MRI
Issue number4
Early online date17 May 2020
Accepted/In press1 Jan 2020
E-pub ahead of print17 May 2020
PublishedAug 2020

King's Authors


Prostate cancer is the commonest malignancy to affect men in the United Kingdom. Extraprostatic disease detection at staging and in the setting of biochemical recurrence is essential in determining treatment strategy. Conventional imaging including computed tomography and bone scintigraphy are limited in their ability to detect sites of loco-regional nodal and metastatic bone disease, particularly at clinically relevant low prostate-specific antigen levels. The use of positron emission tomography-computed tomography has helped overcome these deficiencies and is leading a paradigm shift in the management of prostate cancer using a wide range of radiopharmaceuticals. Their mechanisms of action, utility in both staging and biochemical recurrence, and comparative strengths and weaknesses will be covered in this article.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454